Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells

Yun Qiu, Lakshmeswari Ravi, Hsing Jien Kung

Research output: Contribution to journalArticle

258 Citations (Scopus)

Abstract

Interleukin-6 (IL-6) is a cytokine that was initially recognized as a regulator of immune and inflammatory responses, but it also regulates the growth of many tumour cells, including prostrate carcinoma. Overexpression of the growth-factor receptors ErbB2/neu and ErbB3 has been implicated in the neoplastic transformation of prostate carcinoma. Here we show that treatment of the prostate cancer cell line LNCaP with IL-6 induces tyrosine phosphorylation of ErbB2 and ErbB3, but not ErbB1/EGFR. We also show that ErbB2 forms a complex with the gp130 subunit of the IL-6 receptor in an IL- 6-dependent manner. This association is important because the inhibition of ErbB2 activity results in abrogation of IL-6-induced MAPK activation. Thus ErbB2 is a critical component of IL-6 signalling through the MAP kinase pathway. These data show how a cytokine receptor can diversify its signalling pathways by engaging with a growth-factor receptor kinase.

Original languageEnglish
Pages (from-to)83-85
Number of pages3
JournalNature
Volume393
Issue number6680
DOIs
Publication statusPublished - May 7 1998
Externally publishedYes

Fingerprint

Prostate
Interleukin-6
Carcinoma
Growth Factor Receptors
Interleukin-6 Receptors
Cytokine Receptors
MAP Kinase Signaling System
Tyrosine
Prostatic Neoplasms
Phosphotransferases
Phosphorylation
Cytokines
Cell Line
Growth
Neoplasms

ASJC Scopus subject areas

  • General

Cite this

Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. / Qiu, Yun; Ravi, Lakshmeswari; Kung, Hsing Jien.

In: Nature, Vol. 393, No. 6680, 07.05.1998, p. 83-85.

Research output: Contribution to journalArticle

Qiu, Yun ; Ravi, Lakshmeswari ; Kung, Hsing Jien. / Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. In: Nature. 1998 ; Vol. 393, No. 6680. pp. 83-85.
@article{abc2f4d0e0fa42ae84fd10dcb030c746,
title = "Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells",
abstract = "Interleukin-6 (IL-6) is a cytokine that was initially recognized as a regulator of immune and inflammatory responses, but it also regulates the growth of many tumour cells, including prostrate carcinoma. Overexpression of the growth-factor receptors ErbB2/neu and ErbB3 has been implicated in the neoplastic transformation of prostate carcinoma. Here we show that treatment of the prostate cancer cell line LNCaP with IL-6 induces tyrosine phosphorylation of ErbB2 and ErbB3, but not ErbB1/EGFR. We also show that ErbB2 forms a complex with the gp130 subunit of the IL-6 receptor in an IL- 6-dependent manner. This association is important because the inhibition of ErbB2 activity results in abrogation of IL-6-induced MAPK activation. Thus ErbB2 is a critical component of IL-6 signalling through the MAP kinase pathway. These data show how a cytokine receptor can diversify its signalling pathways by engaging with a growth-factor receptor kinase.",
author = "Yun Qiu and Lakshmeswari Ravi and Kung, {Hsing Jien}",
year = "1998",
month = "5",
day = "7",
doi = "10.1038/30012",
language = "English",
volume = "393",
pages = "83--85",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "6680",

}

TY - JOUR

T1 - Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells

AU - Qiu, Yun

AU - Ravi, Lakshmeswari

AU - Kung, Hsing Jien

PY - 1998/5/7

Y1 - 1998/5/7

N2 - Interleukin-6 (IL-6) is a cytokine that was initially recognized as a regulator of immune and inflammatory responses, but it also regulates the growth of many tumour cells, including prostrate carcinoma. Overexpression of the growth-factor receptors ErbB2/neu and ErbB3 has been implicated in the neoplastic transformation of prostate carcinoma. Here we show that treatment of the prostate cancer cell line LNCaP with IL-6 induces tyrosine phosphorylation of ErbB2 and ErbB3, but not ErbB1/EGFR. We also show that ErbB2 forms a complex with the gp130 subunit of the IL-6 receptor in an IL- 6-dependent manner. This association is important because the inhibition of ErbB2 activity results in abrogation of IL-6-induced MAPK activation. Thus ErbB2 is a critical component of IL-6 signalling through the MAP kinase pathway. These data show how a cytokine receptor can diversify its signalling pathways by engaging with a growth-factor receptor kinase.

AB - Interleukin-6 (IL-6) is a cytokine that was initially recognized as a regulator of immune and inflammatory responses, but it also regulates the growth of many tumour cells, including prostrate carcinoma. Overexpression of the growth-factor receptors ErbB2/neu and ErbB3 has been implicated in the neoplastic transformation of prostate carcinoma. Here we show that treatment of the prostate cancer cell line LNCaP with IL-6 induces tyrosine phosphorylation of ErbB2 and ErbB3, but not ErbB1/EGFR. We also show that ErbB2 forms a complex with the gp130 subunit of the IL-6 receptor in an IL- 6-dependent manner. This association is important because the inhibition of ErbB2 activity results in abrogation of IL-6-induced MAPK activation. Thus ErbB2 is a critical component of IL-6 signalling through the MAP kinase pathway. These data show how a cytokine receptor can diversify its signalling pathways by engaging with a growth-factor receptor kinase.

UR - http://www.scopus.com/inward/record.url?scp=0032492879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032492879&partnerID=8YFLogxK

U2 - 10.1038/30012

DO - 10.1038/30012

M3 - Article

VL - 393

SP - 83

EP - 85

JO - Nature

JF - Nature

SN - 0028-0836

IS - 6680

ER -